Get started
Author

Cheng Liao

Observed institution: Jiangsu Hengrui Medicine (China)
ORCID: 0000-0003-2974-2158
Observed ORCIDs: 0000-0003-2974-2158, 0009-0004-6849-9124
OpenAlex ID: A5081261914
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
2012 · Daigen Xu, Yong Kim, et al. · Journal of Pharmacology and Experimental Therapeutics · 143
3‑Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models
2012 · Michael Soth, Johannes C. Hermann, et al. · Journal of Medicinal Chemistry · 68
Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders
2013 · Seng-Lai Tan, Cheng Liao, et al. · Pharmacology & Therapeutics · 65
Rational Design of Highly Selective Spleen Tyrosine Kinase Inhibitors
2012 · Matthew C. Lucas, David M. Goldstein, et al. · Journal of Medicinal Chemistry · 52
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy
2013 · Cheng Liao, Jonathan Hsu, et al. · Arthritis Research & Therapy · 46
Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors
2013 · Fernando Padilla, Niala Bhagirath, et al. · Journal of Medicinal Chemistry · 43
Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints
2012 · Jonathan Hsu, Yajuan Gu, et al. · Immunology Letters · 37
Using Ovality to Predict Nonmutagenic, Orally Efficacious Pyridazine Amides as Cell Specific Spleen Tyrosine Kinase Inhibitors
2014 · Matthew C. Lucas, Niala Bhagirath, et al. · Journal of Medicinal Chemistry · 31
Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
2025 · Yuan Lin, Kan Lin, et al. · Molecular Cancer Therapeutics · 10
A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells
2024 · Yuan Lin, Xue Wang, et al. · Communications Biology · 10
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity
2024 · Jun Zhang, Lei Zhou, et al. · Cancer Biology & Therapy · 7
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2025 · Simeng Chen, Yuan Lin, et al. · Molecular Cancer Therapeutics · 3
Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases
2024 · Guolin Zhao, Zhijun Wang, et al. · Journal of Inflammation Research · 3
PDF
HRA00129-C004, a Novel c-Met Antibody–Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles
2025 · Yunan Tian, Jieqiong Zhang, et al. · Molecular Cancer Therapeutics · 2
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025 · Li-Min Wang, Changyong Yang, et al. · Molecular Cancer Therapeutics · 2
Development of a Pharmacodynamic Assay Based on PLCγ2 Phosphorylation for Quantifying Spleen Tyrosine Kinase (SYK)–Bruton’s Tyrosine Kinase (BTK) Signaling
2013 · Jonathan Hsu, Jun Zhang, et al. · SLAS DISCOVERY · 2
Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases
2025 · Xiangli Han, Changyong Yang, et al. · Journal of Inflammation Research · 1
PDF
Supplementary Figure S4 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
2026 · Yuan Lin, Kan Lin, et al.
Supplementary Table S1 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
2026 · Yuan Lin, Kan Lin, et al.
Supplementary Figure S2 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
2026 · Yuan Lin, Kan Lin, et al.
Supplementary Figure S1 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
2026 · Yuan Lin, Kan Lin, et al.
Supplementary Figure S3 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
2026 · Yuan Lin, Kan Lin, et al.
Supplementary Figure S5 from Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
2026 · Yuan Lin, Kan Lin, et al.
A pilot study of a personalized cancer vaccine in combination with immune checkpoint inhibitor in advanced pancreatic cancer.
2026 · Fei Wang, Wenwen Zhang, et al. · Journal of Clinical Oncology
Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adebrelimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC).
2026 · Si Shi, Jin Xu, et al. · Journal of Clinical Oncology
Works count: 93
Citation count: 525
H-index: 10
I10-index: 10
Year
Topic
Type